このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

パーキンソン病のためのAAV2-hAADC(PDCS-01) (PDCS-01)

2026年10月30日 更新者:Russell Lonser

若年発症パーキンソン病患者の被殻および尾状核への前頭経路を用いたMRI誘導対流注入によるAAV2-hAADCのオープンラベル安全性および有効性試験

This study is looking at whether a gene therapy called AAV2-hAADC is safe and may help people with Parkinson's Disease.

AAV2-hAADC is intended to increase the levels of dopamine in your brain. It contains a virus called adeno-associated virus 2 (AAV2) that has been modified to carry the genetic code for an enzyme called Aromatic L-Amino Acid Decarboxylase, or AADC for short.

In this study, AAV2-hAADC is delivered to two parts of the brain called the putamen and the caudate. Increasing the amount of AADC gene in these parts of the brain converts more levodopa into dopamine, the chemical that is lacking in PD.

調査の概要

状態

まだ募集していません

介入・治療

研究の種類

介入

入学 (推定)

9

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Male and female adults 18-75 years of age (inclusive), at the time of signing the informed consent.

  2. Diagnosed with idiopathic Parkinson's Disease as defined by the following:

    a. Presence of bradykinesia PLUS any of the following: i. Rigidity ii. Resting tremor iii. Postural instability

  3. Disease duration since diagnosis of >3 years.

  4. Patient reported symptom onset prior to the age of 50 (inclusive).

  5. Modified Hoehn & Yahr Staging ≥2.5 in the practically defined OFF medication state (≥ 12 hours from last dose of anti-parkinsonian medications)

  6. Disabling motor complications with an average of ≥3 hours of OFF time per day during waking hours within 7 days of the screening visit as confirmed by the Parkinson's Disease (PD) diary.

  7. International Parkinson and Movement Disorder Society (MDS) Unified Parkinson's Disease Rating Scale (UPDRS) Part III (total motor) score ≥25 in the clinically defined OFF state.

  8. Unequivocal responsiveness to dopaminergic therapy for a minimum of 1 year, including a 30% or greater improvement in the UPDRS III (motor score) between ON and OFF states, as determined by the Investigator after overnight withdrawal of Parkinson's medications.

  9. In the judgment of the Investigator, a stable, optimal regimen of Parkinson's medications for at least 4 weeks prior to screening evaluation.

  10. In the judgment of the Investigator, stable Parkinson's features and symptoms for at least 4 weeks prior to screening evaluation.

  11. Laboratory values prior to surgery:

    1. Platelets >100E9/L (transfusion independent)
    2. Prothrombin time (PT)/partial thromboplastin time (PTT) in normal range and international normalized ratio (INR) ≤1.3
    3. Absolute neutrophil count >1.5E9/L
    4. Hemoglobin >10.0 g/dL
    5. Aspartate aminotransferase or alanine aminotransferase <2.5U/L × the upper limit of normal
    6. Total bilirubin <2.5 mg/dL
    7. Serum creatinine ≤1.5 mg/dL
    8. Hematocrit >34%
    9. White blood cell count <12E9/L
    10. Estimated glomerular filtration rate ≥30 mL/min.
  12. Medically and cognitively capable of comprehending and signing the informed consent, as well as undergoing and complying with the surgical procedure and protocol requirements as determined by review of medical records, medical history, and clinical evaluation.

  13. Ability to travel to study visits alone or able to designate a care partner who agrees to accompany the participant to study visits as determined by discussion with the participant, care partner (if applicable), and Investigator.

  14. Agrees to defer any neurological surgery, including deep brain stimulation, until the 12-month study visit is completed.

Exclusion Criteria:

  1. Atypical or secondary parkinsonism, including but not limited to symptoms resulting from trauma, brain tumor, infection, cerebrovascular disease, other neurological disease, or to drugs, chemicals, or toxins, as determined by the Investigator.
  2. Presence of clinically significant cognitive impairment as defined by a Montreal Cognitive Assessment (MoCA) score of less than 241 at screening and/or clinical diagnosis of dementia by Investigator based on MoCA diagnostic criteria.
  3. Presence or history of psychosis, except for minor psychosis.
  4. Presence of severe depression, as indicated by a BDI-II score >28 within 5 years of screening evaluation.
  5. Active suicidal ideation as indicated by positive response to items 4 or 5 on the screening C-SSRS, or any history of a suicide attempt
  6. Presence of impulse control disorder, defined as a total score ≥10 on the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS).
  7. History of substance use disorder within 2 years of screening evaluation, as determined from interview with the participant and/or review of medical records.
  8. Brain imaging abnormalities in the striatum or other regions that would substantially increase risk of surgery in the opinion of the investigator.
  9. Contraindication to magnetic resonance imaging (MRI) and/or gadolinium (e.g., ProHance [gadoteridol]).
  10. Coagulopathy or inability to temporarily stop any anticoagulation or antiplatelet therapy for at least 2 weeks during the perioperative period.
  11. Prior stereotactic brain surgery including lesioning procedures, deep brain stimulation, infusion therapies or any other prior brain surgery that could complicate the study procedure and/or negatively impact study evaluations as determined from participant interview, screening MRI, and/or review of medical records.
  12. Prior gene transfer, as determined from participant interview or review of medical records.
  13. History of stroke, poorly controlled or significant cardiovascular disease, diabetes, or any other acute or chronic medical condition that would unreasonably increase the risks of the study procedures, as determined from interview with the participant and/or review of medical records.
  14. History of malignancy other than treated carcinoma in situ within 3 years of screening evaluation.
  15. Clinically apparent or laboratory-detected infection (including acute or chronic scalp infection) at the time of screening or baseline evaluations or immediately prior to surgery that would be a contraindication to surgery.
  16. Prior or current treatment with any investigational agent within 5 half-lives or 30 days (whichever is shorter).
  17. Any factors, medical or social, which would likely cause the inability to comply with the procedures of the protocol, including completion of Parkinson's Disease (PD) diaries, frequent and prolonged study visits (including off medication visits) and travel, in the judgment of the Investigator.
  18. Chronic immunosuppressive therapy, including chronic steroids, immunotherapy, cytotoxic therapy, and chemotherapy as determined by participant interview and/or medical record.
  19. Any serious medical condition or abnormal finding on physical examination or laboratory investigation that would substantially increase the risks of the study procedures in the opinion of the investigator.
  20. Any medical condition that is likely to lead to disability during the study and interfere with or confound study assessments (including but not limited to orthopedic conditions, spinal disorders, neuropathy, myelopathy, severe pulmonary or cardiac disease, and compromised nutritional states), as determined from interview with the participant and/ or review of medical records.
  21. Pregnant and lactating women.
  22. Male or female with reproductive capacity who is unwilling to use barrier contraception for 6 months after surgery.
  23. Ongoing treatments that might interfere with interpretation of the study outcome, including antipsychotic medications, apomorphine, or levodopa infusion therapy (Duopa).
  24. Plans to participate in any other therapeutic intervention study within 12 months after surgery.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Dose 1 (Low Dose)

Total Dose (vg): up to 4.2E12

The purpose of this study is to investigate AAV2-hAADC gene therapy (the study drug) for the treatment of moderately-advanced PD with motor fluctuations.

AAV2-hAADC gene therapy works by using a modified virus called adeno-associated virus 2 (AAV2). This virus is naturally-occurring and not associated with any disease. The virus' DNA has been changed so that it can deliver the human enzyme called Aromatic L-Amino Acid Decarboxylase (AADC). This enzyme converts levodopa into dopamine. AAV2-hAADC can enter brain cells and transfer the copy of the AADC gene directly into these cells. Once the gene is inside the brain cells, those cells will make AADC. By increasing the levels of AADC, we aim to increase the levels of dopamine and improve the symptoms of PD.

AAV2-hAADC will be delivered through a brain surgery to two parts of the brain called the putamen and the caudate. These parts of the brain are involved in PD.

The goal of this study is to assess whether infusing AAV2-h

実験的:Dose 2 (High Dose)

Total Dose (vg): up to 1.3E13

The purpose of this study is to investigate AAV2-hAADC gene therapy (the study drug) for the treatment of moderately-advanced PD with motor fluctuations.

AAV2-hAADC gene therapy works by using a modified virus called adeno-associated virus 2 (AAV2). This virus is naturally-occurring and not associated with any disease. The virus' DNA has been changed so that it can deliver the human enzyme called Aromatic L-Amino Acid Decarboxylase (AADC). This enzyme converts levodopa into dopamine. AAV2-hAADC can enter brain cells and transfer the copy of the AADC gene directly into these cells. Once the gene is inside the brain cells, those cells will make AADC. By increasing the levels of AADC, we aim to increase the levels of dopamine and improve the symptoms of PD.

AAV2-hAADC will be delivered through a brain surgery to two parts of the brain called the putamen and the caudate. These parts of the brain are involved in PD.

The goal of this study is to assess whether infusing AAV2-h

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Adverse Events
時間枠:Through 3 year Follow-up

Assessment of AEs or SAEs and their relationship to the study procedure and study drug (graded as definite, probable, possible, unlikely, or unrelated).

Through 3 year Follow-up
MRI findings
時間枠:Through Month 6 Follow-up

Intraoperative and post-operative MRI findings

Through Month 6 Follow-up
Physical Exam and labs
時間枠:Through 3 year Follow-up

Changes from baseline in physical examination findings and routine clinical laboratory analysis (hematology, clinical chemistries, immunologic assessments).

Through 3 year Follow-up
C-SSRS
時間枠:Through 3 year Follow-up

Changes in Columbia-Suicide Severity Rating Scale (C-SSRS) results

Through 3 year Follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2028年11月1日

研究の完了 (推定)

2029年3月1日

試験登録日

最初に提出

2025年11月24日

QC基準を満たした最初の提出物

2025年11月24日

最初の投稿 (実際)

2025年12月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年10月30日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する